A study of AB-423 in the treatment of Hepatitis B

Trial Profile

A study of AB-423 in the treatment of Hepatitis B

Phase of Trial: Phase I

Latest Information Update: 03 Aug 2017

At a glance

  • Drugs AB 423 (Primary)
  • Indications Hepatitis B
  • Focus Adverse reactions
  • Most Recent Events

    • 03 Aug 2017 According to an Arbutus Biopharma Corporation media release, top-line results from this trial are expected in the fourth quarter of 2017.
    • 31 Mar 2017 Status changed from planning to recruiting, as reported in an Arbutus Biopharma media release.
    • 21 Mar 2017 Aaccording to an Arbutus Biopharma media release, this study will initiate in 1Q 2017.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top